Rani Therapeutics Holdings, Inc.
RANI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.04 | 0.08 | -0.10 |
| FCF Yield | -27.72% | -31.06% | -19.46% | -19.41% |
| EV / EBITDA | -4.55 | -2.99 | -5.00 | -4.93 |
| Quality | ||||
| ROIC | -130.03% | -84.28% | -59.12% | -45.05% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.64 | 0.87 | 1.12 | 0.55 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,062,558.57% | 1,062,558.57% | 1,062,558.57% | 1,009,147.55% |
| Free Cash Flow Growth | 13.20% | 28.87% | 5.60% | -1.77% |
| Safety | ||||
| Net Debt / EBITDA | -1.93 | -1.13 | -1.35 | -1.81 |
| Interest Coverage | -10.01 | -11.98 | -12.74 | -13.31 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 313.95 | 37.47 |